EP3802562A1 - Nouvelle utilisation pharmaceutique - Google Patents

Nouvelle utilisation pharmaceutique

Info

Publication number
EP3802562A1
EP3802562A1 EP19810206.3A EP19810206A EP3802562A1 EP 3802562 A1 EP3802562 A1 EP 3802562A1 EP 19810206 A EP19810206 A EP 19810206A EP 3802562 A1 EP3802562 A1 EP 3802562A1
Authority
EP
European Patent Office
Prior art keywords
compound
formulation
kit
parts
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19810206.3A
Other languages
German (de)
English (en)
Other versions
EP3802562A4 (fr
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Jan-Christer Janson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enlitisa Shanghai Pharmaceutical Co Ltd
Original Assignee
Jiangyin Usun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Usun Pharmaceutical Co Ltd filed Critical Jiangyin Usun Pharmaceutical Co Ltd
Publication of EP3802562A1 publication Critical patent/EP3802562A1/fr
Publication of EP3802562A4 publication Critical patent/EP3802562A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Definitions

  • This invention relates to the new use of a known compound in human medicine, and to pharmaceutical compositions comprising it.
  • the invention relates to the use of the compound and those compositions in the treatment of inflammation.
  • Inflammation is typically characterised as a localised tissue response to e.g. invasion of microorganisms, certain antigens, damaged cells or physical and/or chemical factors.
  • the inflammatory response is normally a protective mechanism which serves to destroy, dilute or sequester both the injurious agent and the injured tissue, as well as to initiate tissue healing.
  • Inflammation may result from physical trauma, infection, some chronic diseases (e.g. psoriasis and autoimmune diseases, such as rheumatoid arthritis) and/or chemical and/or physiological reactions to external stimuli (e.g. as part of an allergic response) .
  • a complex series of events may be involved, in which inflammatory mediators increase blood flow and dilation of local blood vessels, resulting in redness and heat, the exudation of fluids, often resulting in localised swelling, leukocytic migration into the inflamed area, and pain.
  • tissue-damaging inflammation Many conditions/disorders are characterized by, and/or are caused by, abnormal, tissue-damaging inflammation. Such conditions are typically characterized by activation of immune defence mechanisms, resulting in an effect that is more harmful than beneficial to the host, and are generally associated with varying degrees of tissue redness or hyperemia, swelling, hyperthermia, pain, itching, cell death, tissue destruction, cell proliferation and/or loss of function. Examples include inflammatory bowel diseases, rheumatoid arthritis, multiple sclerosis, psoriasis, glomerulonephritis and transplant rejection.
  • a complex series of events results in inflammatory changes such as increased blood flow through dilation of local blood vessels, resulting in redness and heat, the extravasation of leukocytes and plasma, often resulting in localised swelling, activation of sensory nerves (resulting in pain in some tissues) and loss of function.
  • inflammatory changes are triggered by a cascade of cellular and biochemical events involving cells like neutrophils, monocytes, macrophages and lymphocytes together with inflammatory mediators such as vasoactive amines, cytokines, complement factors and reactive oxygen species.
  • inflammation plays a key role in the wound healing process. Wounds and burns can therefore be classified as conditions with which inflammation is associated. Traditional thinking in the art is that antiinflammatory drugs should not be applied directly to open wounds, as this would be detrimental to the progress of wound healing.
  • Mussel adhesive protein also known as Mytilus edulis foot protein (mefp)
  • mefp Mytilus edulis foot protein
  • the adhesive protein is secreted by mussels from the byssus gland where it is produced and stored.
  • a water-proof bond is formed which fixes the mussel to the solid object.
  • Mussels are typically attached, in groups, to coastal reefs or to the bottoms of ships. The bond is incredibly strong, having the ability to resist wave impacts in coastal waters.
  • mfp-1 sometimes referred to as “mefp-1” , hereinafter used interchangeably
  • mfp-2 sometimes referred to as “mefp-1” , hereinafter used interchangeably
  • mfp-2/mefp-2 mfp-3/mefp-3
  • mfp-4/mefp-4 mfp-5/mefp-5
  • mfp-6/mefp-6 the collagens pre-COL-P, pre-COL-D and pre-COL-NG
  • PTMP proximal thread matrix protein
  • DTMP distal proximal thread matrix protein
  • All mussel adhesive proteins including sub-types thereof, have two structural characteristics, in that they comprise: (1) lysine, such that the protein carries a high positive charge loading (due to the NH 2 termini) ; (2) 3, 4-dihydroxyphenylalanine (DOPA, dopamine) , the catechol part of which is responsible for the formation of strong covalent bonds and consequently the ability of mussel adhesive proteins to bind to solid surfaces.
  • lysine such that the protein carries a high positive charge loading (due to the NH 2 termini)
  • DOPA 4-dihydroxyphenylalanine
  • dopamine catechol part of which is responsible for the formation of strong covalent bonds and consequently the ability of mussel adhesive proteins to bind to solid surfaces.
  • Products based on mussel adhesive protein products are presently used in a limited number of fields (including micro-cellular bonding, as tissue bonding agents and the treatment of wounds and burns) .
  • Commercial products are either directly used as a solution of mussel adhesive protein or are stored as a freeze-dried powder for dissolution prior to use.
  • mefp-1 consists of 70 to 90 tandem repeats of the decapeptide: Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (see Waite, Int. J. Adhesion and Adhesives, 7, 9 (1987) ) .
  • This decapeptide seqience may by isolated as a low molecular weight derivative of naturally-occurring MAPs, or may be synthesized, for example as described by Yamamoto in J. Chem. Soc., Perkin Trans. 1, 613 (1987) . See also Dalsin et al, J. Am. Chem. Soc., 125, 4253 (2003) .
  • DOPA residue is considered to be essential to the activity of MAPs, such as mefp-1.
  • MAPs such as mefp-1.
  • a different amino acid such as tyrosine
  • an (isolated) peptide compound comprising, or preferably consisting of, the sequence
  • an (isolated) peptide compound of the above-mentioned sequence for use in veterinary science and/or as a cosmetic.
  • the compounds (including regioisomers and stereoisomer) and salts thereof that are disclosed herein for the uses mentioned herein are referred to hereinafter together as “the compounds of the invention” .
  • Compounds of the invention include regioisomers within certain amino acids in the above structure (e.g. Hyp and Tyr) , as well as mixtures of such regioisomers.
  • regioisomers within certain amino acids in the above structure (e.g. Hyp and Tyr) , as well as mixtures of such regioisomers.
  • included within the definition of Tyr are, not only tyrosine (4-hydroxyphenylalanine) , but also 2-and 3-hydroxyphenylalanine, and included within the definition of Hyp are 4-hydroxyproline, 3-hydroxyproline and 5-hydroxyproline.
  • the Hyp residue that is adjacent to the Tyr residue in a compound of the invention may be 3-hydroxyproline
  • the Hyp residue that is adjacent to the Thr residue in a compound of the invention may be 4-hydroxyproline. It is more preferred that the Hyp residues are both 4-hydroxyproline.
  • certain amino acids in the sequence comprise further chiral carbon atoms. All such stereoisomers and mixtures (including racemic mixtures) thereof are included within the scope of the invention.
  • included within the definition of Hyp are trans-4-hydroxy-L-proline, cis-4-hydroxy-L-proline, trans-3-hydroxy-L-proline, cis-3-hydroxy-L-proline trans-5-hydroxy-L-proline and cis-5-hydroxy-L-proline, however we prefer that the Hyp that is employed in compounds of the invention is 4-hydroxy-L-proline.
  • Salts that may be mentioned include pharmaceutically-acceptable and/or cosmetically-acceptable salts, such as pharmaceutically-and/or cosmetically-acceptable acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of free peptide with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration) .
  • Salts may also be prepared by exchanging a counter-ion of active ingredient in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.
  • Preferred salts include, for example, hydrochloride, bisulfate, maleate, mesylate, tosylate, alkaline earth metal salts, such as calcium and magnesium, or alkali metal salts, such as sodium and potassium salts.
  • Compounds of the invention are useful because they possess pharmacological activity.
  • the compounds of the invention are useful as human and animal medicine. They are therefore indicated as pharmaceuticals (and/or in veterinary science) , although they may also be used as cosmetics and/or as part of a medical device.
  • compounds of the invention may possess pharmacological activity as such, certain pharmaceutically-acceptable (e.g. “protected” ) derivatives of compounds of the invention may exist or may be prepared which may not possess such activity, but which may be administered and thereafter be metabolised or chemically transformed to form compounds of the invention.
  • Such compounds (which may possess some pharmacological activity, provided that such activity is appreciably lower than that of the active compounds to which they are metabolised/transformed) may therefore be described as “prodrugs” of compounds of the invention.
  • references to prodrugs will include compounds that form a compound of the invention, in an experimentally-detectable amount, within a predetermined time, following administration. All prodrugs of the compounds of the invention are included within the scope of the invention.
  • Compounds of the invention are particularly useful in the treatment of inflammation.
  • the “treatment of inflammation” includes the treatment of inflammation in any organ of the body (including soft tissue, joints, nerves, the vascular system, internal organs, especially mucosal surfaces, and particularly the skin) , irrespective of the cause, and also includes all such inflammatory disorders or conditions, and/or disorders or conditions characterized by inflammation (e.g. as a symptom) .
  • Inflammatory conditions may be (and are typically) characterized by activation of immune defence mechanisms, resulting in an effect that is more harmful than beneficial to the host.
  • Such conditions are generally associated with varying degrees of tissue redness or hyperemia, swelling, edema, hyperthermia, pain (including aching) , exudation of body fluids, itching (pruritis) , cell death and tissue destruction, cell proliferation, and/or loss of function.
  • Inflammatory conditions include arteritis, diabetes mellitus, metabolic syndrome, rosacea, asthma and allergy, ankylosing spondylitis, chronic obstructive pulmonary disease, gouty arthritis, inflammatory bowel disease (such as Crohn’s disease and ulcerative colitis) , multiple sclerosis, osteoarthritis, pancreatitis, prostatitis, psoriatic arthritis, rheumatoid arthritis, tendinitis, bursitis, Sjogren’s syndrome, systemic lupus erythematosus, uveitis, urticaria, vasculitis, mastocytosis, diabetic vascular complications, migraine, atherosclerosis and associated cardiovascular disorders.
  • a disease state characterised by inflammation that may be mentioned is chronic obstructive pulmonary disease (COPD) .
  • COPD chronic obstructive pulmonary disease
  • a further disease state characterised by inflammation that may be mentioned is inflammatory bowel disease, including Crohn’s disease and,
  • Inflammatory conditions that may be more especially mentioned include inflammations of the skin or mucosa (including the oral, nasal, ocular, vaginal, cervical and/or anorectal mucosae, more particularly the oral or nasal mucosae) , such as inflammation resulting from infections (such as viral and/or bacterial infections) , or allergic/atopic conditions (such as rhinitis, pharyngitis, periodontitis, gingivitis, xerophthalmia, conjunctivitis, dermatitis, urticaria (hives) and food allergy) ; and other inflammatory conditions, such as herpes, drug eruptions, polymorphous light eruptions, sunburn, early manifestations of skin cancers (erythema-like skin lesions) , pathological hair loss (including following skin grafting) , chemo rash, psoriasis, erythema multiforme, folliculitis, eczema and external otitis.
  • compounds may be used to treat certain conditions characterised by inflammation, and/or with which inflammation is associated.
  • Such conditions may include wounds (including abrasions (scratches) , incisions (including operative incisions) , lacerations, punctures, avulsions, bruising and scarring) , and burns (including inflammation resulting from surgery following burns, such as skin grafting) , and other conditions, such as hemorrhoids.
  • Wounds of the skin or mucosa may arise from internal or external physical injury to the membrane surface, or may be caused by (i.e. be a symptom of an underlying physiological disorder) .
  • wounds may be caused by sharp objects (cuts, incisions, punctures) or blunt objects/mechanical forces (lacerations, abrasions, avulsions) , physical blows (bruises) , heat or chemicals (burns and blisters) , UV light (sunburn) , cold (chilblains or frostbite) .
  • Wounds may be superficial (damage only to the epidermis and/or dermis) or may be full thickness wounds (damage below the epidermis and/or dermis) .
  • subcutaneous and/or submucosal tissues such as muscles, bones, joints, and even internal organs, may be damaged.
  • Compounds of the invention may be used to relieve the pain (including aching) associated with inflammation and/or wounding.
  • compounds of the invention may be used to relieve procedural pain and/or non-procedural pain.
  • procedural pain i.e. operation pain
  • non-procedural refers to general pain that is associated with inflammation and/or wounding (e.g. pain associated with dental ulcers, burns and/or scars) , and is not a consequence of a particular medical intervention.
  • Compounds of the invention may be used to treat not only the inflammation, pain including aching) and/or pruritis (itching) associated with the wound itself and the healing process, but also they may be used to prevent the exudation of body fluids from wounds, the risk of infection, and also the prevention of physiological reactions that result from inflammation and/or wound healing processes, such as scarring and melanin pigmentation.
  • Scarring is a consequence of inflammation and/or wound healing and is a general term for the formation of fibrotic tissue that is a consequence of such inflammation/healing.
  • Compounds of the invention may also be useful in the suppression of the production of melanin pigmentation that may result from inflammation and/or wound healing.
  • Compounds of the invention may also be useful in the suppression of disorders associated with melanin pigmentation, such as chloasma, freckles, melanosis, malar rash and other chromatosis, skin cancers with melanoma, and chromatosis that is caused by exposure to the sun or skin diseases like acne.
  • Wounds may also arise as a consequence of diseases or disorders. Such wounds may include blistering and/or ulcers of the skin and mucosa. These are common conditions that are often long-lasting and difficult to treat. Skin tissues can often be damaged, removed, liquefied, infected and/or necrotic. Ulcers can lead to secondary consequences to health particularly if they become infected, are hard to heal and are costly. They can also cause significant psychological stress and economic loss to patients, affecting both general well-being and quality of life.
  • inflammatory skin conditions or diseases in which compounds of the invention find particular utility include psoriasis, acne, eczema and dermatitis, especially allergic/atopic dermatitis, as well as in the treatment of rhinitis, especially allergic rhinitis, hemorrhoids and chronic obstructive pulmonary disease.
  • Psoriasis is a chronic, inflammatory skin disease with a tendency to recur (some patients never heal during their entire life) .
  • Clinical manifestations of psoriasis mainly include erythema and scales. It can occur over the whole body, but is more commonly observed on the scalp and limbs.
  • Acne is a follicular (pilosebaceous unit) chronic, inflammatory skin disease, the occurrence of which is closely related to main factors like hypersteatosis, blocked pilosebaceous ducts (including closed and open comedones) , bacterial infection and inflammatory reactions, that tends to occur during youth, characterised by multiform skin lesions on the face.
  • the term acne thus includes regular acne and acne rosacea (i.e. copper nose) .
  • Eczema is a skin inflammatory reaction with strong itching caused by a variety of internal and external factors. It has three phases, acute, sub-acute, and chronic. In the acute phase, there is a tendency for the production of exudates, while the chronic phase includes infiltration and hypertrophy. Skin lesions are often itchy and recur easily.
  • Dermatitis is a common skin disease characterised by coarseness, redness, itching, eczema, and dryness. Small lumps, refractory ulcers, and pigmented spots caused by dermatitis may, if not treated promptly, develop to basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. Dermatitis may be caused by various internal and external infectious or non-infectious factors, including substances (contact dermatitis) or allergy (allergic/atopic dermatitis) .
  • seborrheic dermatitis seborrheic dermatitis
  • steroid-dependent dermatitis including light-sensitive seborrheid, perioral dermatitis, rosacea-like dermatitis, steroid-rosacea, steroid-induced rosacea, iatrosacea, steroid dermatitis resembling rosacea, topical corticosteroid-induced rosacea-like dermatitis and, more particularly, facial corticosteroid addictive dermatitis (FCAD) or facial corticosteroid-dependent dermatitis (FCDD) , as characterised by flushing, erythema, telangiectasia, atrophy, papules and/or pustules in the facial area after long-term treatment with (including uncontrolled use, abuse or misuse of) topical corticosteroids; see, for example, Xiao et al, J. Dermatol.
  • Rhinitis is irritation and inflammation of the mucous membrane inside the nose. Common symptoms of rhinitis include a stuffy nose, runny nose, sneezing and post-nasal drip. The most common kind of rhinitis is allergic rhinitis, caused by an allergen, such as pollen, dust, mould, or flakes of skin from certain animals. The compounds of the invention may give rise to relief of eye itichiness, even when administered nasally (i.e. to the nasal mucosa) .
  • Hemorrhoids are swellings caused by larged inflammation of the hemorrhoidal blood vessels found inside or around the the rectum and anus. Symptoms include bleeding (i.e. wounding) after the passage of a stool, prolapse of the hemorrhoid, mucus discharge and itchiness, soreness, redness and swelling in the area of the anus. Hemorrhoids are believed to be a consequence of an increase of pressure in the abdomen, for example, as a result of constipation or diarrhea.
  • COPD chronic obstructive pulmonary disease
  • emphysema damage to the alveoli
  • chronic bronchitis long-term inflammation of the airways
  • COPD occurs when the lungs become inflamed, damaged and narrowed. The damage to the lungs is usually irreversaible and results in an impairment of the flow of air into and out of the lungs.
  • Symptoms of COPD include breathlessness, productive cough, frequent chest infections and persistent wheezing. The most common cause of the disease is smoking, although other risk factors include high levels of air pollution and ocupational exposure to dust, chemicals and fumes.
  • Compounds of the invention may have positive effects in mitigating erythema, redness and swelling, edema, blisters, and bullous pemphigoid caused by various conditions including those mentioned generally and specifically herein, and may inhibit exudation of subcutaneous tissue fluid, and suppressing itching and pain caused by such inflammatory conditions.
  • Mucosal inflammation such as oral mucositis, aphthous ulcers, otitis media, laryngitis, tracheitis, esophagitis, gastritis, enteritis and enterocolitis (including bacillary dysentery, chronic amoebic dysentery, schistosomiasis, nonspecific ulcerative colitis and regional enteritis) , cervicitis and endocervicitis, endometritis, inflammation caused by inhalation injury and the like, as well as mucosal inflammation associated with cancers, and infections (e.g.
  • viral infections such as the common cold or influenza
  • mucosal surfaces such as those in the oral cavity, the nasopharynx, the ear, the throat, the trachea, the gastrointestinal tract, the cervix, etc.
  • bone tumors osteoma, osteoid osteoma, chondrom
  • Nerve inflammation such as peripheral polyneuritis, facial neuritis, peripheral neuritis, subcutaneous neuritis, ulnar neuritis, intercostal neuritis, etc.
  • Subcutaneous and submucosal soft tissue inflammation such as myositis, ligamentitis, tendonitis, panniculitis capsulitis, lymphadenitis, bubonadentitis, tonsillitis, synovitis, fasciitis, and soft tissue inflammation caused by injuries, contusion or laceration of muscles, ligaments, fascia, tendons, membrana synovialis, fat, articular capsules, and lymphoid tissue.
  • Vascular inflammation such as allergic leukocytoclastic vasculitis, allergic cutaneous vasculitis, polyarteritis nodosa, thrombotic vasculitis, granulomatous vasculitis, lymphocytic vasculitis, vasculitis with abnormalities in blood composition, and rheumatic vasculitis, as well as vascular inflammation associated with vascular cancers caused by allergic leukocytoclastic vasculitis, polyarteritis nodosa, thrombotic vasculitis, granulomatous vasculitis, lymphocytic vasculitis, vasculitis with abnormalities in blood composition, and rheumatic vasculitis.
  • Inflammation of the internal organs such as the heart, stomach, intestine, lung, liver, spleen, kidney, pancreas, bladder, ovary, and prostate, including but not limited to pericarditis, myocarditis, endocarditis, pneumonia, hepatitis, splenitis, nephritis pancreatitis, cystitis, oophoritis, prostatitis and treatment of gastric ulcer.
  • Inflammation of the eye and surrounding area such as conjunctivitus, keratitis (e.g. acute epithelial keratitis, nummular keratitis, interstitial keratitis, disciform keratitis, neurotrophic keratitis, mucous plaque keratitis, herpes simplex keratitis, herpes zoster keratitis, bacterial keratitis, fungal keratitis acanthamoebic keratitis, onchocercal keratitis, superficial punctate keratitis, ulcerative keratitis, exposure keratitis photokeratitis and ccontact lens acute red eye) , optic neuritis, etc.
  • keratitis e.g. acute epithelial keratitis, nummular keratitis, interstitial keratitis, disciform keratitis, neurotrophic keratitis, mu
  • Inflammation associated with rheumatism such as rheumatic vasculitis, rheumatoid arthritis, rheumatic bone diseases, ankylosing spondylitis, bursitis, Crohn's disease, gout, infectious arthritis, juvenile idiopathic arthritis, osteoarthritis, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, scleroderma, Sjogren's syndrome, spondyloarthropathies, systemic lupus erythematosus, tendinitis, etc.
  • rheumatic vasculitis such as rheumatic vasculitis, rheumatoid arthritis, rheumatic bone diseases, ankylosing spondylitis, bursitis, Crohn's disease, gout, infectious arthritis, juvenile idiopathic arthritis, osteoarthritis, osteoporosis, polymyalgia
  • Compounds of the invention may also be used in the treatment of certain specific diseases of the respiratory system, such as pulmonary cystic fibrosis, usual interstitial pneumonia, allergic pneumonia, asbestosis, emphysema, pulmonary heart disease, pulmonary embolism, etc.
  • pulmonary cystic fibrosis usual interstitial pneumonia, allergic pneumonia, asbestosis, emphysema, pulmonary heart disease, pulmonary embolism, etc.
  • a specific disease state that may be mentioned in idiopathic pulmonary fibrosis.
  • Idiopathic pulmonary fibrosis is a diffuse and fatal pulmonary interstitial disease with pathological features including alveolar epithelial damage, massive proliferation of lung fibroblasts, excessive deposition of extracellular matrix, ultimately leading to irreversible lung tissue damage. In the latter stages of the disease, subjects with idiopathic pulmonary fibrosis experience respiratory failure and death. It has been found that compounds of the invention may find utility in the treatment of idiopathic pulmonary fibrosis and/or alleviation of the symptoms associated with the disease.
  • Compounds of the invention may further possess an antioxidation effect, by increasing SOD (superoxide dismutase) production and reducing lipid oxidation. Such compounds and formulations including them may therefore be considered have antioxidant properties.
  • Compounds of the invention may also possess antipyretic properties that allow for the treatment of a fever and/or alleviate the symptoms thereof; for example, by reducing a subject’s body temperature, which results in a reduction of fever. Compounds of the invention and formulations including them may therefore be considered to be antipyretics.
  • a method of treatment of inflammation, of an inflammatory disorder, and/or of a disorder/condition characterised by inflammation comprises the administration of a compound of the invention to a patient in need of such treatment.
  • treatment includes the therapeutic, or palliative, treatment of patients in need of, as well as the prophylactic treatment and/or diagnosis of patients which are susceptible to, inflammation and/or inflammatory disorders.
  • Patients include reptilian, avian and mammalian (particularly human) patients.
  • compounds of the invention are preferably administered locally or systemically, for example orally, intravenously or intraarterially (including by intravascular and other perivascular devices/dosage forms (e.g. stents) ) , intramuscularly, cutaneously, subcutaneously, transmucosally (e.g. sublingually or buccally) , rectally, intravaginally, transdermally, nasally, pulmonarily (e.g. tracheally or bronchially) , preferably topically, or by any other parenteral route, in the form of a pharmaceutical preparation comprising the compound (s) in pharmaceutically acceptable dosage form (s) .
  • Administration by inhalation e.g.
  • nasally is particularly useful when the condition to be treated is rhinitis or inflammation resulting from viral infections of the airways (e.g. common cold, influenza) .
  • Pulmonary administration is particularly useful when the condition to be treated is COPD or IPF.
  • Topical forms of administration may be enhanced by creating a spray comprising active ingredients, e.g. by using a powder aerosol or by way of an aqueous mist using an appropriate atomisation technique or apparatus, such as a nebulizer.
  • Preferred modes of delivery of compounds of the invention include topically to the site of inflammation (e.g. the mucosa, including the lung or, more preferably, the skin) in an appropriate (for example pharmaceutically-and topically-acceptable) vehicle suitable for application to the skin and/or the appropriate mucosal surface, and/or a commercially-available formulation, but may also include oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal or pulmonary delivery.
  • an appropriate (for example pharmaceutically-and topically-acceptable) vehicle suitable for application to the skin and/or the appropriate mucosal surface, and/or a commercially-available formulation, but may also include oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal or pulmonary delivery.
  • Compounds of the invention will generally be administered in the form of one or more for example pharmaceutical formulations in admixture with a (e.g. pharmaceutically acceptable) adjuvant, diluent or carrier, which may be selected with due regard to the intended route of administration (e.g. topical to the relevant mucosa (including the lung) or, preferably, the skin) and standard pharmaceutical or other (e.g. cosmetic) practice.
  • a pharmaceutically acceptable adjuvant, diluent or carrier which may be selected with due regard to the intended route of administration (e.g. topical to the relevant mucosa (including the lung) or, preferably, the skin) and standard pharmaceutical or other (e.g. cosmetic) practice.
  • Such pharmaceutically acceptable carriers may be chemically inert to the active compounds and may have no detrimental side effects or toxicity under the conditions of use.
  • Such pharmaceutically acceptable carriers may also impart an immediate, or a modified, release of the active ingredient.
  • Suitable pharmaceutical formulations may be commercially available or otherwise prepared according to techniques that are described in the literature, for example, Remington The Science and Practice of Pharmacy, 22 nd edition, Pharmaceutical Press (2012) and Martindale –The Complete Drug Reference, 38 th Edition, Pharmaceutical Press (2014) and the documents referred to therein, the relevant disclosures in all of which documents are hereby incorporated by reference. Otherwise, the preparation of suitable formulations including compounds of the invention may be achieved non-inventively by the skilled person using routine techniques.
  • Compounds of the invention may be in the form of an aqueous formulation such as an emulsion, a suspension and/or a solution (e.g. an (optionally) buffered aqueous formulation, such as a physiological saline-containing formulation, a phosphate-containing formulation, an acetate-containing formulation or a borate-containing formulation) , or a freeze-dried powder.
  • a aqueous formulation such as an emulsion, a suspension and/or a solution
  • a solution e.g. an (optionally) buffered aqueous formulation, such as a physiological saline-containing formulation, a phosphate-containing formulation, an acetate-containing formulation or a borate-containing formulation
  • a freeze-dried powder e.g. an (optionally) buffered aqueous formulation, such as a physiological saline-containing formulation, a phosphate-containing formulation, an acetate-containing formulation or a borate-containing
  • Active ingredient may further be combined with appropriate excipents to prepare:
  • ⁇ gel formulations for which suitable gel matrix materials include cellulose derivatives, carbomer and alginates, gummi tragacanthae, gelatin, pectin, carrageenan, gellan gum, starch, Xanthan gum, cationic guar gum, agar, noncellulosic polysaccharides, saccharides such as glucose, glycerin, propanediol, vinyl polymers, acrylic resins, polyvinyl alcohol, carboxyvinyl polymer and, particularly, hyaluronic acid) ;
  • ⁇ lotions for which suitable matrix materials include cellulose derivatives, glycerin, noncellulosic polysaccharides, polyethylene glycols of different molecular weights and propanediol
  • suitable matrix materials include cellulose derivatives, glycerin, noncellulosic polysaccharides, polyethylene glycols of different molecular weights and propanediol
  • pastes or ointments for which suitable paste matrix materials include glycerin, vaseline, paraffin, polyethylene glycols of different molecular weights, etc. ) ;
  • ⁇ creams or foams for which suitable excipients (e.g. foaming agents) include hydroxypropyl methyl cellulose, gelatin, polyethylene glycols of different molecular weights, sodium dodecyl sulfate, sodium fatty alcohol polyoxyethylene ether sulfonate, corn gluten powder and acrylamide) ;
  • suitable excipients e.g. foaming agents
  • suitable excipients include hydroxypropyl methyl cellulose, gelatin, polyethylene glycols of different molecular weights, sodium dodecyl sulfate, sodium fatty alcohol polyoxyethylene ether sulfonate, corn gluten powder and acrylamide
  • ⁇ powder aerosols for which suitable excipients include mannitol, glycine, dextrin, dextrose, sucrose, lactose, sorbitol and polysorbates, e.g. a dry powder inhalant) ; and/or
  • liquid (aerosol) sprays for oral use or for inhalation for which suitable excipients include viscosity modifiers, such as hyaluronic acid, sugars, such as glucose and lactose, emulsifiers, buffering agents, alcohols, water, preservatives, sweeteners, flavours, etc. ) .
  • viscosity modifiers such as hyaluronic acid
  • sugars such as glucose and lactose
  • emulsifiers emulsifiers
  • buffering agents alcohols, water, preservatives, sweeteners, flavours, etc.
  • Moisturizing agents such as glycerol, glycerin, polyethylene glycol, trehalose, glycerol, petrolatum, paraffin oil, silicone oil, hyaluronic acid and salts (e.g sodium and potassium salts) thereof, octanoic/capyic triglyceride, and the like; and/or antioxidants, such as vitamins and glutathione; and/or pH modifiers, such as acids, bases and pH buffers, may also be included in such formulations, as appropriate.
  • surfactants/emulsifiers such as hexadecanol (cetyl alcohol) , fatty acids (e.g.
  • stearic acid sodium dodecyl sulfate (sodium lauryl sulfate)
  • sorbitan esters e.g. sorbitan stearate, sorbitan oleate, etc.
  • monoacyl glycerides such as glyceryl monostearate
  • polyethoxylated alcohols polyvinyl alcohols, polyol esters, polyoxyethylene alkyl ethers (e.g. polyoxyethylene sorbitan monooleate)
  • polyoxyethylene castor oil derivatives ethoxylated fatty acid esters, polyoxylglycerides, lauryl dimethyl amine oxide, bile salts (e.g.
  • sodium deoxycholate, sodium cholate) phospholipids, N, N-dimethyldodecylamine-N-oxide, hexadecyltrimethyl-ammonium bromide, poloxamers, lecithin, sterols (e.g. cholesterol) , sugar esters, polysorbates, and the like; preservatives, such as phenoxyethanol, ethylhexyl glycerin, and the like; and thickeners, such as acryloyldimethyltaurate/VP copolymer, may be included.
  • stearic acid glyceryl monostearate, hexadecanol, sorbitan stearate, cetyl alcohol, octanoic/capric glyceride etc. may be included, particularly in cream formulations.
  • Compounds of the invention and may further be combined with an appropriate matrix material to prepare a dressing or a therapeutic patch for application on a biological surface, such as the skin or a mucosal surface.
  • a matrix material such as gauze, non-woven cloth or silk paper.
  • the therapeutic patch may alternatively be, for example, a band-aid, a facial mask, an eye mask, a hand mask, a foot mask, etc.
  • Vaseline may be employed for use in applying such dressings to wounds, but we have also found that ointments based on PEGs (e.g. PEG 400) may be combined with matrix materials to prepare dressings without the need to use vaseline.
  • PEGs e.g. PEG 400
  • Compounds of the invention may also be combined in treatment with one or more growth factors selected from platelet-type growth factors (including platelet-derived growth factors, PDGFs) ; osteosarcoma-derived growth factors (ODGF) , epidermal growth factors (EGFs) , transforming growth factors (TGF ⁇ and TGF ⁇ ) , fibroblast growth factors ( ⁇ FGF, ⁇ FGF) , insulin-like growth factors (IGF-I, IGF-II) , nerve growth factors (NGF) , interleukin-type growth factors (IL-1, IL-1, IL-3) , erythropoietin (EPO) , and colony stimulating factor (CSF) .
  • platelet-type growth factors including platelet-derived growth factors, PDGFs
  • ODGF epidermal growth factors
  • TGF ⁇ and TGF ⁇ transforming growth factors
  • ⁇ FGF, ⁇ FGF fibroblast growth factors
  • IGF-I, IGF-II insulin-like growth factors
  • a composition comprising a compound of the invention and one or more pharmaceutically-acceptable excipient, such as an adjuvant, diluent or carrier.
  • a pharmaceutically-acceptable excipient such as an adjuvant, diluent or carrier.
  • Preferred formulations are suitable for application locally to e.g. the mucosa (including the lung) or, more preferably, the skin and therefore comprise a topically-acceptable adjuvant, diluent or carrier.
  • formulations comprising compounds of the invention may be suitable for, adapted for, and/or packaged and presented for topical adminstration (e.g. to the the lung, the mucosa or to the skin) , for example for the treatment of a disorder, including inflammation, an inflammatory disorder and/or a condition characterised by inflammation (e.g. as a symptom) by way of direct topical adminstration of that formulation (e.g. to the lung, the mucosa or, preferably, to the skin) .
  • topical adminstration e.g. to the the lung, the mucosa or to the skin
  • topical formulations of the invention may be used in any and all conditions described herein, including treatments of inflammation, in the treatment of any and all inflammatory disorder (s) , and/or in the treatment of any and all condition (s) characterised by inflammation, as hereinbefore mentioned, defined or described.
  • Topical (e.g. liquid-or (e.g. aqueous) solution-based) formulations of the invention may be particularly useful in wound recovery, and may alleviate pain (including aching) and, particularly, pruritis/itching that is associated with the wound itself and the wound healing process.
  • Such topical formulations of the invention may be particularly useful in the prevention and/or suppression of the exudation of body fluids from wounds, particularly during the acute inflammation stage, for example during the first 48 hours, after a burn or wound has been inflicted. This prevents the risk of infection, and other physiological reactions.
  • Such topical formulations of the invention may also be particularly useful in the prevention and/or suppression of scarring and melanin pigmentation (vide supra) , whether associated with wounds or otherwise.
  • Administration of active ingredients may be continuous or intermittent.
  • the mode of administration may also be determined by the timing and frequency of administration, but is also dependent, in the case of the therapeutic treatment of inflammation, on the severity of the condition.
  • compounds of the invention may be administered at varying therapeutically effective doses to a patient in need thereof.
  • the amount of active ingredient in a formulation will depend on the severity of the condition, and on the patient, to be treated, but may be determined by the skilled person.
  • the medical practitioner or other skilled person, will be able to determine routinely the actual dosage, which will be most suitable for an individual patient, depending on the severity of the condition and route of administration.
  • the dosages mentioned herein are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • Doses may be administered between once and four times daily.
  • Appropriate concentrations of compounds of the invention in an aqueous solution product may be about 0.01 (e.g. about 0.1) to about 15.0 mg/mL, in all cases calculated as the free (non-salt) peptide.
  • Appropriate topical doses of compounds of the invention are in the range of about 0.05 to about 50 ⁇ g/cm 2 of treated area, such as about 0.1 (e.g. about 0.5) to about 20 ⁇ g/cm 2 of treated area, including about 1 to about 10 ⁇ g/cm 2 ) of treated area, such as about 5 ⁇ g/cm 2 of treated area, in all cases calculated as the free (non-salt) peptide.
  • pH values of formulations comprising compounds of the invention are in the range of about 1.0 to about 9.0 (for example about 3.0 to about 8.0) .
  • compounds of the invention are considerable more stable at all pH values, including neutral and basic pHs, than for example MAPs, and isolated compounds that consist of the mefp-1 decapeptide sequence.
  • the dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the mammal over a reasonable timeframe (as described hereinbefore) .
  • a mammal particularly a human
  • the selection of the exact dose and composition and the most appropriate delivery regimen will also be influenced by inter alia the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient, as well as the age, condition, body weight, sex and response of the patient to be treated, and the stage/severity of the disease, as well as genetic differences between patients.
  • compounds of the invention may also be combined with one or more active ingredients that are useful in the treatment of inflammation and/or inflammatory disorders (other antiinflammatory agents) .
  • Such patients may thus also (and/or already) be receiving therapy based upon administration of one or more of such other active ingredients, by which we mean receiving a prescribed dose of one or more of those active ingredients mentioned herein, prior to, in addition to, and/or following, treatment with a compound of the invention.
  • anti-inflammatory agents that may be used in combination with compounds of the invention in the treatment of inflammation include therapeutic agents that are useful in the treatment of inflammation and/or of diseases characterised by inflammation as one of its symptoms.
  • antiinflammatory agents may include NSAIDs, leukotriene receptor antagonists (e.g. montelukast, for example as described hereinafter) , corticosteroids, analgesics and certain enzymes, such as trypsin, for example as described hereinafter.
  • Compounds of the invention may also be combined with leukotriene B4 (LTB4) .
  • compounds of the invention may also be combined for use in the treatment of inflammation with one or more mussel adhesive proteins (MAPs) , which includes any adhesive protein that may be derived from mussel species, such as Mytilus edulis (blue mussel) , including full length proteins, including all sub-types, that are or may be derived from mussels, such as the collagens pre-COL-P, pre-COL-D and pre-COL-NG, the mussel feet matrix proteins PTMP and DTMP, and, more preferably, mfps or mefps, such as mefp-2, mefp-3, mefp-4, mefp-5, mefp-6 and especially mefp-1, and includes mixtures or combinations of any of these proteins, such as mefps.
  • MAPs mussel adhesive proteins
  • the purity of the principal MAP sub-type e.g. mefp-1 is at least 25%by weight of the total amount of any such mixture.
  • Naturally-occuring MAPs may be prepared, for example by mixed adsorption chromatography (see Chinese Patent No. ZL200710179491.0) , by carboxymethyl ion exchange chromatography (see Chinese Patent No. ZL200710179492.5) , and/or by salting out and dialysis (Chinese Patent No. ZL200910087567.6) .
  • Commericial sources of MAPs include USUN Bio Co. (China; sold as MAP Medical ) , BD Biosciences (USA) , Kollodis (South Korea) and Biopolymer (Sweden) .
  • MAPs may alternatively be produced using known recombinant DNA methods.
  • Derivatives (e.g. pharmaceutically-acceptable derivatives) of MAPs may also be combined with compounds of the invention and include compounds with, for example, molecular weights in the range of about 500 to about 2,000 (e.g. about 1,500, such as about 1,200 including about 800 Da) which may allow for easier penetration through biological membranes, such as the skin barrier or a mucosal surface.
  • Such derivatives may also include other compounds that comprise amino acid sequences that are the same as, or are (e.g. minor) variants of, sequences that have been identified in naturally-occurring MAPs, and which may be synthesized by chemical and/or biological processes (e.g. chemical modifications of naturally-occurring MAPs, or direct synthesis) .
  • (e.g. minor) variants of amino acid sequences identified in naturally-occurring MAPs” we mean variations in those sequences that do not negatively affect the requisite properties of the relevant naturally-occuring MAP to a measurable degree.
  • the isolated decapeptide compound of the sequence: Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (mefp-1 decapeptide) is a pharmaceutically-acceptable low molecular weight derivative of MAP that may be combined with a compound of the invention.
  • Such derivatives of MAPs may be employed in combination products according to the invention alone, or in combination with one or more other such derivatives, and/or one or more of the aforementioned full length MAPs.
  • Appropriate concentrations of MAPs and derivatives thereof in an aqueous solution topical formulation product may be about 0.01 (e.g. about 0.1) to about 15.0 (e.g. about 1.5) mg/mL, and appropriate pH values are in the range of about 1.0 to about 7.0 (for example about 3.0 to about 6.5) , irrespective of whether the formulation employed is a combined preparation or a kit of parts as hereinbefore described.
  • Suitable commercial sources of such aqueous solutions include USUN Bio Co., Jiangyin, Jiangsu province, China.
  • Appropriate topical doses of MAPs and derivatives thereof are in the range of about 0.1 to about 50 ⁇ g/cm 2 of treated area, such as about 1 to about 20 ⁇ g/cm 2 of treated area, including about 2 to about 10 ⁇ g/cm 2 of treated area, such as about 5 ⁇ g/cm 2 of treated area.
  • Combinations of compounds of the invention and mefp-1 have been found to be of particular utility in the treatment of inflammatory bowel diseases, such as ulcerative colitis and, in particular, in arresting the bleeding in patients having such a disease.
  • LTB4 to treat wounds and burns
  • montelukast to treat inflammation generally
  • trypsin to treat inflammation of the mucosa associated with e.g. viral infections
  • Compounds of the invention may also be combined with other therapeutic agents which, when administered, are known to give rise to inflammation as a side-effect.
  • the active ingredients may be administered together in the same formulation, or administered separately (simultaneously or sequentially) in different formulations.
  • Such combination products provide for the administration of compounds of the invention in conjunction with the other therapeutic agent, and may thus be presented either as separate formulations, wherein at least one of those formulations comprises a compound of the invention, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single formulation including a compound of the invention and the other therapeutic agent) .
  • a pharmaceutical formulation including a compound of the invention; another antiinflammatory agent, or agent known to give rise to inflammation as a side- effect; and a pharmaceutically-acceptable adjuvant, diluent or carrier (which formulation is hereinafter referred to as a “combined preparation” ) ; and
  • composition including a compound of the invention in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier;
  • components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.
  • a method of making a kit of parts as defined above comprises bringing component (A) , as defined above, into association with a component (B) , as defined above, thus rendering the two components suitable for administration in conjunction with each other.
  • components (A) and (B) of the kit of parts may be:
  • kit of parts comprising:
  • kits of parts described herein may comprise more than one formulation including an appropriate quantity/dose of a compound of the invention, and/or more than one formulation including an appropriate quantity/dose of another antiinflammatory agent, in order to provide for repeat dosing. If more than one formulation (comprising either active compound) is present, such formulations may be the same, or may be different in terms of the dose of either compound, chemical composition (s) and/or physical form (s) .
  • kits of parts as described herein by “administration in conjunction with” , we include that respective formulations comprising a compound of the invention and other antiinflammatory agent are administered, sequentially, separately and/or simultaneously, over the course of treatment of the relevant condition.
  • the term “administration in conjunction with” includes that the two components of the combination product (compound of the invention and other antiinflammatory agent) are administered (optionally repeatedly) , either together, or sufficiently closely in time, to enable a beneficial effect for the patient, that is greater, over the course of the treatment of the relevant condition, than if either a formulation comprising compound of the invention, or a formulation comprising the other agent, are administered (optionally repeatedly) alone, in the absence of the other component, over the same course of treatment. Determination of whether a combination provides a greater beneficial effect in respect of, and over the course of treatment of, a particular condition will depend upon the condition to be treated or prevented, but may be achieved routinely by the skilled person.
  • the term “in conjunction with” includes that one or other of the two formulations may be administered (optionally repeatedly) prior to, after, and/or at the same time as, administration of the other component.
  • the terms “administered simultaneously” and “administered at the same time as” include that individual doses of the relevant compound of the invention and other antiinflammatory agent are administered within 48 hours (e.g. 24 hours) of each other.
  • a process for the preparation of a combined preparation as hereinbefore defined comprises bringing into association a compound of the invention, the other antiinflammatory agent, or agent known to give rise to inflammation as a side-effect, and at least one (e.g. pharmaceutically-acceptable) excipient.
  • Compounds of the invention have the advantage that they may be used in variety of conditions characterised by inflammation, whether that condition is an organic inflammatory disease per se or is associated with, or is characterised by, inflammation (e.g. a wound, a burn or a viral infection) .
  • Compounds of the invention also have the advantage in that they are physico-chemically stable to processes such as oxidation at a variety of pHs, including neutral and basic pHs, when compared to similar compounds known in the prior art, such as MAPs and isolated mefp-1 decapeptide.
  • the uses and methods described herein may also have the advantage that, in the treatment of the conditions mentioned hereinbefore, they may be more convenient for the physician and/or patient than, be more efficacious than, be less toxic than, have a broader range of activity than, be more potent than, produce fewer side effects than, or that it/they may have other useful pharmacological properties over, similar methods (treatments) known in the prior art, whether for use in the treatment of inflammation, inflammatory disorders, or disorders characterised by inflammation as a symptom (including wounds) , or otherwise.
  • Figure 1 shows ELISA test results for various inflammatory markers obtained from exudates from air pouches induced in mice according to Example 1, tested with various test compounds
  • Figure 2 shows the effect on acute healing of wounds inflicted on mice when treated with various test compounds
  • Figures 3 to 5 shows ELISA test results for inflammatory markers (Hyp, VEGF and TNF- ⁇ 1, respectively) obtained from samples taken from the respective wounds in those mice.
  • Fmoc-Lys-Boc-Wang resin (0.3 mmol/g; GLS180322-41301, GL Biochem, Shanghai, China) was loaded into a reaction column.
  • DCM methylene chloride
  • DMF N, N-dimethylformamide
  • the liquid was drained to obtain the resin-bound polypeptide.
  • mice Healthy adult male C57BL/6 mice weighing between 20 and 30 g were supplied by Nanjing Biomedicial Research Institute of Nanjing University (NBRI) . Prior to any experiments being conducted, mice were housed under standardized conditions (at a constant temperature of 22 ⁇ 2°C, with alternating 12 hour periods of light and darkness) , and were fed on a standard mouse diet with water, for about a week.
  • NBRI Nanjing Biomedicial Research Institute of Nanjing University
  • Air pouches were produced by subcutaneous injection of sterile air (5 mL) into the intrascapular area of the mice. After three days, another injection of air (3 mL) was performed to maintain the pouches. In order to induce acute inflammation, three days after this final injection, animals received an injection of sterile carrageenan solution (CP Kelco, Taixing, Jiangsu province, China. 1%, 0.5 mL; produced by adding 0.1 g of carrageenan powder into a beaker containing 10 mL of 0.9%saline solution and stirring) . Mice were pre-treated with test samples or vehicle 1 hour before and 23 hours after the carrageenan injection into the subcutaneous air pouch. Animals were sacrificed 24 hours after the carrageenan injection.
  • sterile carrageenan solution CP Kelco, Taixing, Jiangsuzhou, China. 1%, 0.5 mL; produced by adding 0.1 g of carrageenan powder into a beaker containing 10 mL of 0.9%s
  • Skin biopsies were taken from the air pouches. A part of the biopsy was fixed in formalin (produced by adding ultra pure water to 50 mL of a 40%formaldehyde solution (Nanchang Rain Dew Experimental Equipment Co., Ltd., Nanchang, Hubei province, China) up to a total volume of 500 mL) and analyzed by histological embedding in paraffin wax, sectioning and staining.
  • formalin produced by adding ultra pure water to 50 mL of a 40%formaldehyde solution (Nanchang Rain Dew Experimental Equipment Co., Ltd., Nanchang, Hubei province, China) up to a total volume of 500 mL
  • the cavity was washed with 4 mL of sterile phosphate buffer solution (pH 7.4; prepared by dissolving 4 g of NaCl, 0.1 g of KCl, 1.749 g of Na 2 HPO 4 ⁇ 12H 2 O and 0.1 g of KH 2 PO 4 in ultrapure water, adjusting the pH to 7.4 with HCl and diluting with water to a total volume of 500 mL) .
  • pH 7.4 prepared by dissolving 4 g of NaCl, 0.1 g of KCl, 1.749 g of Na 2 HPO 4 ⁇ 12H 2 O and 0.1 g of KH 2 PO 4 in ultrapure water, adjusting the pH to 7.4 with HCl and diluting with water to a total volume of 500 mL
  • Exudates were collected and volumes were quantified. The exudates were centrifuged at 3000 rpm for 10 minutes at 4°C, and the supernatants were collected and stored at -20°C for ELISA analysis using standard ELISA test kits from Beijing 4A Biotech Co., Ltd. (Beijing) and an ELISA reader (SH-1000 Hitachi, Japan) for tissue necrosis factor alpha (TNF- ⁇ ) , interleukin 1 beta (IL-1 ⁇ ) , interleukin 6 (IL-6) .
  • TNF- ⁇ tissue necrosis factor alpha
  • IL-1 ⁇ interleukin 1 beta
  • IL-6 interleukin 6
  • MAP solution was prepared as follows. Blue mussels were harvested in the coastal area of Shandong province, China. Mussel feet were collected, cut into small pieces and homogenized in an extraction buffer comprising 5%acetic acid in 4 mol/L of aqueous urea. The crude extracts were collected after centrifuging and then purified by liquid chromatography. The purified protein (semi-finished product; concentration 8 mg/mL; purity as measured by HPLC 91.72%; pH 4.2) was stored at 0°C. The solutions that was employed below was prepared by adding saline solution to this semi-finished product to obtain the concentrations described in Table 1.
  • Compound A An isolated compound consisting of the mefp-1 decapeptide sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys (hereinafter “Compound A” ) was purchased from Innovagen (Innovagen AB, Lund, Sweden) . It was stored as a powder at -20°C and dissolved in saline water at a concentration of 0.6 mg/ml, pH 5.5.0.5 mL of the solution was injected.
  • Compound B The compound of the invention (Compound B) was synthesized by GL Biochem (Shanghai) Ltd. according to Example 1 above, and was also stored as a powder at -20°C and was dissolved in saline water at a concentration of 0.6 mg/ml, pH 5.5. 0.5 mL of the solution was injected.
  • the histological specimens were analyzed and an inflammation score, an activity score (i.e. the number and density of neutrophils shown in pathological slides, indicating the degree of inflammation and, in the case of open wound and infective diseases, the degree of infection) , an edema score and a fibroblast proliferation score were estimated as follows.
  • the HE stained slices were observed under an optical microscope and were scored (1, 2 or 3 points) according to the perceived inflammation level (in cases showing only a small amount of inflammatory cells scattered in the area -1 point (mild) ; in cases where many inflammatory cells were observed -2 points (moderate) ; and, in cases with diffuse infiltration -3 points (severe) .
  • a similar scoring system was employed for edema levels (3 points for most severe and 1 point for mild) after overall observation. Scores for neutrophils employed the same methodology as that employed for inflammatory cells.
  • mice 6-8 weeks old male C57BL/6 mice were supplied by Changzhou Cvens Experimental Animal Co. Ltd (Changzhou, Jiangsuzhou, China) . Prior to any experiments being conducted, mice were housed under standardized conditions (at a constant temperature of 22 ⁇ 2°C, with alternating 12 hour periods of light and darkness) , and were fed on a standard mouse diet with water, for about a week.
  • An EMS skin biopsy punch (Electron Microscopy Sciences, P. O. Box 550, 1560 Industry Road, Hatfield, PA, USA) with a 18 mm diameter was used to make a round wound on the back. The full thickness of skin was removed and the depth of the wound reached the fascia. Wounds were left open without a suture.
  • mice were treated with different drugs.
  • Different drugs were administrated topically at 50 ⁇ L/wound, once daily from Day 0 to Day 12, as shown in Table 3 below.
  • the control group did not have a wound inflicted.
  • the model group was given same amount of normal saline. There were 8 mice in each group.
  • rhEGF Recombinant Human Epidermal Growth Factor
  • rhEGF Recombinant Human Epidermal Growth Factor
  • the lyophilized rhEGF powder (100000IU/vial) was dissolved in 20 mL of normal saline to make a solution with a concentration of 5000 IU/mL.
  • the working dose of rhEGF for this experiment was 1285 IU/wound.
  • Compound A was also obtained from GL Biochem (Shanghai) Ltd.
  • the peptide powders were stored at -20°C and dissolved in saline at concentrations of 61.8 ⁇ g/mL (Compound A) , and 61 ⁇ g/mL (Compound B) . 50 ⁇ L of the solutions were applied onto the wound surfaces.
  • the unhealed wound area was expressed as a percentage of the original wound area:
  • a 0 and A t refer to the initial area at Day 0 and the wound area at the date of measurement (time t) , respectively.
  • mice were sacrificed and the wound tissue taken by the same biopsy punch used to create the wound. Then 5 mm of tissue was cut off from the center of the sample and was preserved in 10%neutral buffered formalin (Nanchang Rain Dew Experimental Equipment Co., Ltd., Nanchang, Hubei province, China) , and analyzed by histological embedding (HE) in paraffin wax, sectioning and staining.
  • HE histological embedding
  • HE and Masson stained paraffin sections were analyzed under an optical microscope. Skin regeneration, fibroblastic proliferation, collagen regeneration scores and inflammation scores were estimated.
  • Tissuelyser Shanghai Jingxin Industrial Development Co., Ltd., Shanghai, China
  • VEGF Vascular endothelial growth factor
  • TGF- ⁇ 1 transforming growth factor beta 1
  • Hyp hydroxyproline
  • the above data show that a low dose of Compound B improves wound healing.
  • the improvement rate was defined as (remaining wound ratio in treatment group/remaining wound ratio in model group) x 100%.
  • the improvement rate in the Compound B group was about 10%.
  • the wound Hyp ( ⁇ g/mg) content which is an indicator of collagen regeneration, is shown in Table 5 below and in Figure 3.
  • VEGF content (pg/g) are tabulated in Table 6 below and are shown graphically in Figure 4.
  • Compound B has increased the VEGF production in the wounded tissue for about 56.7%in comparison with that in model group.
  • TGF- ⁇ 1 content (pg/g) are tabulated in Table 7 below and are shown graphically in Figure 5.
  • Compound B (see Example 1 above) was dissolved in Water for Injection (WFI; prepared from a TC-RO-0.25/h-2 Water Treatment System, Yangzhou Tiancheng Water Treatment Devices &Engineering Co., Ltd., Yangzhou, China) .
  • WFI Water for Injection
  • the concentration was 0.3 mg/mL.
  • a mixture was then made comprising sorbitan stearate (2 g) , cetyl alcohol (4 g) , octanoic/capric glyceride (6 g) and glyceryl monostearate (3 g) (all Sinopharm Chemical Reagent Co. Ltd. ) , which was stirred and heated to 85°C to melt the mixture completely.
  • Glycerin (5 g; Sinopharm Chemical Reagent Co. Ltd. ) and ammonium acryloyldimethyltaurate/VP copolymer (0.13 g; Clariant Chemical (Guangzhou) Co., Ltd., China) were mixed with 68.86 g of WFI. This mixture was stirred and heated to 85°C to provide a homogeneous colloidal suspension.
  • copolymer/water mixture was added to the sorbitan stearate-containing mixture, which was then quickly stirred using emulsification equipment for 5 minutes. The resultant emulsion was cooled to room temperature.
  • the Compound B solution was then added to the resultant mixture with stirring to obtain the finished cream.
  • the concentration of Compound B in the final cream was 0.1 mg/g.
  • Subjects with closed comedones (blocked pores) and in an acute attacking period of acne were enrolled in the study. Symptoms included sebaceous glands blocked by keratinocytes, forming a slightly hard lump and a protruding white head.
  • the antioxidant capacity of Compound B was determined using a 2, 2-diphenyl-1- (2, 4, 6-trinitrophenyl) hydrazyl (DPPH) assay.
  • the DPPH method is one of the most commonly used methods in determination of antioxidant capacity.
  • DPPH is a stable, nitrogen-centred free radical with a dark purple solution and a maximum absorption peak at 517 nm.
  • a free radical scavenger When a free radical scavenger is present in the reaction system, it can be paired with a single electron of DPPH ⁇ , and the absorption peak at 517 nm is gradually dissipated.
  • the degree of colour change bears a stoichiometric relationship to the number of paired electrons.
  • antioxidant activity can be measured according to the change of absorbance. The greater the inhibition rate, the stronger the antioxidant capacity.
  • Peptide solutions were prepared by dissolving 0.6 g of peptide powder in 1 mL of distilled water.
  • the DPPH clearance rate for Compound A was 52.11%. That for Compound B was much less, at 8.9%, representing a significant improvement in antioxidant capacity.
  • the peak area presented in Table 10 above as an area %of Day 0’s result represents the peptide concentration.
  • peak areas of three samples of Compound B were almost unchanged.
  • the peak area at pH 5 was unchanged, but at pH 7.2 and pH 8.1, the peak areas decreased significantly, which indicates that the concentration of peptide decreased with time.
  • Polyethylene glycol 3350 (21.3 g; Sinopharm Chemical Reagent Co. Ltd) was dissolved in in polyethylene glycol 400 (58.5 g) by heating to 60°C with stirring. After this solution had cooled to 40-50°C, the solution containing Compound B and montelukast was added to it with stirring, followed by mixing for 5 to 10 minutes. Cooling to room temperature gave the finished product.
  • the ointment was coated evenly on a gauze with a flat plate. Cooling to room temperature gave the finished dressing.
  • Compound B (30 mg; see Example 1 above) was dissolved in 10 mL of water. Trypsin (30 mg; Sichuan Deebio Pharmacutical Co. Ltd., Guanhan, Sichuan, China) was dissolved in another 10 mL of water.
  • a aerosol formulation was prepared essentially as described in Example 9 above, from 20 mg of Compound B and 30 mg of trypsin, this time without glycerol and in a total of 99.32 mL of water.
  • the subject that was enrolled in the study had a viral infection that was self-diagnosed as the common cold.
  • the subject presented symptoms, including cough, sore throat and loss of voice for 2 days.
  • Other anti-cold drugs had not been used prior to treatment.
  • the subject was required to use the liquid spray of Example 10 above in the morning and the evening.
  • mice 40 adult male Sprague Dawley rats, after 7 days of adaptive feeding, were divided into 4 groups: sham-operation group (Sham) , IPF model group (no treatment; Model) , test group (Compound B) and positive control group (Positive Control) .
  • test were administered Compound B, at a dose of 130 ⁇ g/rat, which was introduced by aerosolized inhalation.
  • Oral administration of pirfenidone ( Beijing Continent Pharmaceutical Co., Ltd., Beijing, China) as a 120 mg/kg single-bolus dose served as the positive control.
  • a pulmonary fibrosis model was established by intratracheal instillation of bleomycin.
  • the rats were anaesthetised and placed on an operating table in the supine position, to expose the trachea.
  • Bleomycin (5 mg/kg) saline solution was injected into the trachea through the gap between the tracheal cartilage rings.
  • the sham-operation group were given an equal volume of normal saline.
  • the rats were lifted vertically and were rotated, in order to evenly disperse the drug. Once the rats had recovered, after approximately 5 days, they were administrated the different drugs according to the plan for 28 days, consecutively.
  • the experimental plan was showed in Table 12.
  • the exhaust volume of the atomizing device was 0.15 mL per minute.
  • the inhalation time for each rat was 1 minute.
  • rats were anesthetized by i. p. injection of chloral hydrate. After orbital blood collection, the rats were sacrificed. The thoracic cavity was quickly opened and the lung was collected for further analysis. The lung wet weight was measured, and the lung coefficient was calculated (lung wet weight/rat weight x 1000) . The tissue was stored in refrigerator at -80°C for further use.
  • TGF- ⁇ 1 transformation growth factor
  • TNF- ⁇ tumor necrosis factor- ⁇
  • ⁇ -SMA alpha-smooth muscle actin
  • the lung coefficient value was lower in the Compound B group than that in the Model group, which indicates that Compound B can reduce edema.
  • the lower MDA value and higher SOD value in the Compound B group show that Compound B has an antioxidant effect, by increasing SOD production and reducing lipid oxidation.
  • mice were randomly divided into 3 groups according to their body weight, labelled a CMC-Na (Negative) control group, a dextromethorphan hydrobromide (Positive) control group and a Compound B (B) group. Each group contained 12 mice, with 6 males and 6 females in each.
  • Compound B was administered via atomization inhalation using a YLS-8A Multifunctional cough and sputum inducing device (Jinan Yiyan Science and Technology Co., Ltd. ) (0.15 mL/min) for 1 minute, once daily for 5 days. And the positive control drug was administered once daily by intragastric administration at 10 mg/kg for 5 days.
  • mice were placed in an inverted beaker 1, 2, and 4 hours after the last drug administration. 1 mL of aqueous ammonia (25.0 to 28.0%) was placed on top of a boiling water bath and was evaporated into the beaker.
  • mice to receive ammonia exposure was determined by a method characterized by analyzing data immediately after one test or a batch of tests. The results of the previous analysis determined how to conduct the next test or batch of tests. In this way, the process of experiment-analysis-experiment proceeded sequentially:
  • the difference between the logarithmic value of two adjacent time periods was 0.1.
  • the number of coughs within 1 minute was detected using a stethoscope. If a mouse coughed three or more times over one minute, this was labelled as called ‘cough’ , and less than three times in one minute was labelled ‘cough free’ .
  • the EDT 50 was defined as the ammonia stimulating time at which half mice developed a “cough” , calculated by the equation:
  • EDT 50 lg -1 c/n
  • R is the EDT 50 in treatment group divided by the EDT 50 in the Control group expressed as a percentage.
  • Compound B was dissolved in Injection water (WFI; from a TC-RO-0.25T/h-2 water treatment system, Yangzhou Tiancheng Water Treatment Devices &Engineering Co., Ltd., Yangzhou, China) .
  • the concentration was 0.5 mg/mL. 5 mL was loaded into a plastic water spray bottle.
  • the enrolled subject in the study was inflicted with a common cold for 2 days prior to treatment. Other cold treatments were not used before treatment.
  • Example 14 The same formulation as described in Example 14 above was administered to a subject who enrolled in the study having had got a fever (a body temperature over 38.5°C) for 1 day. Other anti-fever medications were not used prior to treatment.
  • the subject was required to use the aerosol inhalation device in the morning and in the evening by pouring 3 mL of the formulation into an atomizer storage tank connected to an atomizer and a mask, which was worn over the mouth and nose.
  • the enrolled subject was required to use 1 mL of a liquid spray comprising the same formulation as that described in Example 14 above in a water spray bottle on half of her face before and after a lattice laser operation to remove of facial melanin.
  • the subject reported that she did not feel pain during the operation on half of her face to which the spray was applied. Similarly, she felt no pain after the operation. Conversely, pain was felt during the operation on the half of her face that was not sprayed. Furthermore, after the operation, the pain lasted about 2 hours.
  • the subject defecated more than 20 times per day and exhibited severe bleeding from, and ulceration within, the colon.
  • the gel formulation was given by through the anus. After having been given one dose on the first day, the patient defecated just three time on the second day. The subject then received two further doses on the second day. By the third day, bleeding was controlled.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un peptide de séquence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys, ou un sel de celui-ci, destiné à être utilisé en tant que produit pharmaceutique. Le peptide est particulièrement utile dans le traitement d'affections caractérisées par une inflammation, y compris des plaies, des brûlures, des hémorroïdes, le psoriasis, l'acné, la dermatite atopique, la BPCO, la rectocolite hémorragique et l'IPF.
EP19810206.3A 2018-05-28 2019-05-27 Nouvelle utilisation pharmaceutique Pending EP3802562A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018088701 2018-05-28
PCT/CN2019/088593 WO2019228307A1 (fr) 2018-05-28 2019-05-27 Nouvelle utilisation pharmaceutique

Publications (2)

Publication Number Publication Date
EP3802562A1 true EP3802562A1 (fr) 2021-04-14
EP3802562A4 EP3802562A4 (fr) 2022-06-01

Family

ID=68697381

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19810206.3A Pending EP3802562A4 (fr) 2018-05-28 2019-05-27 Nouvelle utilisation pharmaceutique

Country Status (8)

Country Link
US (1) US20210196783A1 (fr)
EP (1) EP3802562A4 (fr)
JP (1) JP2021525242A (fr)
KR (1) KR20210016365A (fr)
CN (1) CN112236440A (fr)
MA (1) MA52794A (fr)
TW (1) TW202016127A (fr)
WO (1) WO2019228307A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3648767A4 (fr) * 2017-07-05 2021-04-28 Jiangyin Mucocare Pharmaceutical Co., Ltd Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule
MA54707A (fr) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes
KR20220079860A (ko) * 2019-09-14 2022-06-14 장인 우선 파마슈티컬 컴퍼니 리미티드 신규 펩티드
CA3160167A1 (fr) * 2019-12-02 2021-06-10 Ming Gu Peptides et leur utilisation dans le traitement d'une inflammation
EP4228641A1 (fr) * 2020-10-13 2023-08-23 Diomed Developments Limited Formulations de gel contenant du montélukast
WO2022193186A1 (fr) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. Nouveaux agents diagnostiques et thérapeutiques
WO2022193185A1 (fr) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. Nouveaux conjugués
WO2024169972A1 (fr) * 2023-02-13 2024-08-22 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. Nouveaux oligopeptides multifonctionnels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831793A4 (fr) * 1995-06-06 2000-11-15 Hemosphere Inc Particules proteiques a usage therapeutique et diagnostique
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1851237A4 (fr) * 2005-02-16 2009-01-07 Univ California Compositions pharmaceutiques pour traiter ou prevenir des affections osseuses
EP2101547B1 (fr) * 2008-03-11 2014-03-05 Vita Zahnfabrik H. Rauter GmbH & Co. KG Four de frittage dentaire et procédé de frittage d'éléments dentaires céramiques
EP2471819B1 (fr) * 2009-08-25 2016-11-09 Postech Academy-Industry- Foundation Coacervat ayant un polymère ionique mélangé à la protéine moulière adhésive ou à une espèce de variome de celle-ci
KR20150014483A (ko) * 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
WO2014186937A1 (fr) * 2013-05-20 2014-11-27 Gao Min Procédé de préparation de gel à base de protéine adhésive de moule, gel à base de protéine adhésive de moule et utilisation associée
US10568938B2 (en) * 2015-07-20 2020-02-25 Jiangyin Bengt I. Samuelsson Institute Of Life Science Co., Ltd. Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2017028025A1 (fr) * 2015-08-14 2017-02-23 江阴市本特塞缪森生命科学研究院有限公司 Produit de protéine adhésive de moule et son utilisation servant à inhiber l'inflammation d'une muqueuse
WO2017181372A1 (fr) * 2016-04-20 2017-10-26 江阴市本特塞缪森生命科学研究院有限公司 Produit de protéine adhésive de moule et son utilisation pour inhiber une inflammation vasculaire
CN106581656A (zh) * 2016-12-30 2017-04-26 江阴贝瑞森生化技术有限公司 一种用于小儿舌舔皮炎的软膏
WO2019011286A1 (fr) * 2017-07-14 2019-01-17 Jiangyin Usun Pharmaceutical Co., Ltd. Utilisation antivirale de protéines adhésives de moule

Also Published As

Publication number Publication date
KR20210016365A (ko) 2021-02-15
MA52794A (fr) 2021-04-14
CN112236440A (zh) 2021-01-15
TW202016127A (zh) 2020-05-01
JP2021525242A (ja) 2021-09-24
US20210196783A1 (en) 2021-07-01
WO2019228307A1 (fr) 2019-12-05
EP3802562A4 (fr) 2022-06-01

Similar Documents

Publication Publication Date Title
AU2018295944B2 (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
WO2019228307A1 (fr) Nouvelle utilisation pharmaceutique
US20210317166A1 (en) Anti-inflammatory use of peptide
EP3678705B1 (fr) Conjugués de montélukast et de peptides
WO2021047648A1 (fr) Nouveaux peptides
WO2020143744A1 (fr) Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes
WO2021110061A1 (fr) Peptides et leur utilisation dans le traitement d'une inflammation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039345

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220502

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 15/00 20060101ALI20220425BHEP

Ipc: A61K 47/10 20170101ALI20220425BHEP

Ipc: A61K 9/00 20060101ALI20220425BHEP

Ipc: A61K 9/06 20060101ALI20220425BHEP

Ipc: A61P 29/00 20060101ALI20220425BHEP

Ipc: A61P 31/00 20060101ALI20220425BHEP

Ipc: A61P 17/02 20060101ALI20220425BHEP

Ipc: A61P 11/00 20060101ALI20220425BHEP

Ipc: A61P 1/00 20060101ALI20220425BHEP

Ipc: A61K 38/08 20190101ALI20220425BHEP

Ipc: C07K 7/06 20060101AFI20220425BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD.